Showing results (51-60 of 83) with videos related to
Sort By:
Pageof 9
European Journal of Radiology|February 22, 2022
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancerJorge E Jimenez, Abeer Abdelhafez, Elizabeth A Mittendorf, et al.American Journal of Cancer Research|March 21, 2020
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancerYu-Yi Chu, Clinton Yam, Mei-Kuang Chen, et al.JCO Precision Oncology|March 14, 2024
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer SubtypesReva K Basho, Li Zhao, Jason B White, et al.Nature Communications|December 1, 2018
High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancerGloria V Echeverria, Emily Powell, Sahil Seth, et al.NPJ Breast Cancer|May 9, 2018
A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer metastasisEmily Powell, Jiansu Shao, Hector M Picon, et al.Cancer|April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumorsDavid S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic VariantJennifer K Litton, Marion E Scoggins, Kenneth R Hess, et al.BMC Cancer|August 15, 2024
Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNAJennifer H Chen, Sridevi Addanki, Dhruvajyoti Roy, et al.Academic Radiology|July 17, 2021
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRosalind P Candelaria, David A Spak, Gaiane M Rauch, et al.JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.Pageof 9